IL10 and rheumatoid arthritis: We have shown that abatacept (1) expands IL-35 and IL-10 producing Breg subtype of RA to a level that associates with disease remittance, and (2) expands LAG3+ cTreg and LAG3+ uTreg of RA at 6 months following treatment.